Victoria Socha

DocwireNews

Immune Checkpoint Inhibitor Response in Patients with mRCCChicago&mdash;Immune checkpoint inhibitors (ICIs) are standard of care for patients with metastatic renal cell carcinoma (mRCC). However, the data on biomarkers to predict patient response to ICIs are scarce. Results from trials of atezolizumab/bevacizumab suggest that tumors with high expression of an effector T-cell gene signature in the tumor (Teffhigh)/PD-L1+ are more likely to respond to ICI.Researchers, led by Jason Zhu, MD, <a href="https://medschool.duke.edu">Duke University School of Medicine</a>, used two gene panels in addition to other markers of inflammation in the tumor microenvironment to correlate with ICI responses. Results of the multicenter study were reported at the ASCO 2019 Annual Meeting in a poster titled Evaluation of Tumor Microenvironment and Biomarkers of Immune Checkpoint Inhibitor (ICI) Response in Metastatic Renal Cell Carcinoma (mRCC).A total of 86 patients with mRCC treated with ICIs were included in the study. RNA sequencing was used to evaluate formalin-fixed paraffin-embedded (FFPE tumor) samples for Teff status. Based on the <a href="https://www.docwirenews.com/docwire-pick/rheumatic-immune-checkpoint-inhibitors/">gene expression patterns of tumors</a> in the study cohort, the researchers analyzed two gene panels: (1) a Teff gene panel (CD8, CD27, IFNG, GZMA, GZMB, PRF1, EOMES, CXCL9, CXCL10, CXCL11, CD274, CTLA4, FOXP3, TIGIT, IDO1, PSMB9, and TAP1); and (2) a 5-gene panel (FOXP3, CCR4, KLRK1, ITK, and TIGIT).Objective response rates (ORRs), defined as complete responses (CRs) and partial responses (PRs), were correlated with programmed death-ligand 1 (PD-L1) status (positivity was defined as &ge;1% TPS based on Dako 33C3 IHC Assay), and tumor mutational burden (TMB) (0-10, 10-20 &ge;20 mut/Mb). Best response to ICI was determined using Response Evaluation in Solid Tumors Criteria version 1.1 criteria. The.re was an association between ORR and inflamed tumor status, Teff gene panel, 5-gene panel PD-L1 status, and TMB.For PD-L1 positive patients, ORR was 50% (n=4/8) compared with 14% (n=9/65) for PD-L1 negative patients (P=.042). Ninety-five percent of tumors (n=82/86) had TMB &lt;10 mut/Mb.Fifty percent of the patients (n=43) were classified as Teffhigh and 50% (n=43) were classified as Tefflow. In the Teffhigh cohort, ORR was 23% compared with 12% in the Tefflow cohort (P=.256). In the 5-gene high cohort, ORR was 31% (n=14/45), compared with 2% (n=1/41) in the 5-gene low cohort (P=.001).In summary, the researchers said, &ldquo;TMB and tumor inflammation based on CD8 did not reliably predict for objective responses in this study of mRCC patients treated with ICIs. Gene expression signatures provide a more comprehensive evaluation of the tumor microenvironment and may lead to better predictive biomarkers for ICI response than individual biomarkers such as PD-L1, TMB, or CD8 expression.&rdquo;Source: Zhu J, Pabla S, Labriola L, et al. Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor (ICI) response in metastatic renal cell carcinoma (mRCC). Abstract of a poster presented at the American Society of Clinical Oncology 2019 Annual Meeting, June 1, 2019, Chicago, Illinois.

Dr. Sadie Dobrozsi, Evolent

Rob Dillard

Genomics Tailors Breast Cancer Care, Cuts Unneeded Chemo

Genetics & Breast Cancer

Andrew Moreno

Extending Anticoagulation is Reasonable in Children with VTE, Data Suggest

Katie Kosko

DESTINY-Breast06: T-DXd Beats Chemo in HER2-Low HR+ mBC

Breast Cancer News

Latest News

Immune Checkpoint Inhibitor Response in mRCC

ASCO 2019

Immune Checkpoint Inhibitor Response in Patients with mRCC ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe